Today: 9 June 2026
DLF hits debt-free milestone after Q3 results — but sales bookings crash and shares slide
23 January 2026
2 mins read

DLF hits debt-free milestone after Q3 results — but sales bookings crash and shares slide

NEW DELHI, Jan 23, 2026, 14:35 (IST)

  • DLF’s Q3 profit jumped roughly 14%, driven by strong collections and rising cash reserves
  • Sales bookings plunged to 4.19 billion rupees amid a halt in new launches
  • The developer reported zero gross debt and finished the quarter with a net cash surplus

Shares of DLF Ltd fell on Friday following a steep decline in sales bookings reported in its Q3 results, even as the company announced it has become gross debt-free for the first time since its 2007 IPO. By mid-afternoon, DLF was trading around 588.5 rupees, down roughly 4% after starting the day higher.

The update arrives amid a tricky period for India’s listed property stocks. Big developers rely on steady collections and strong demand for premium housing, yet investors are pushing for new launches to translate into actual bookings, not merely a catch-up in revenue.

DLF’s debt wipeout marks a milestone markets tend to cheer. The drop in bookings, though, has traders double-checking the calendar, wondering, “What’s actually coming to market next?”

DLF reported a 13.66% rise in profit after tax for the quarter ending Dec. 31, reaching 12.03 billion rupees. Total income surged 42.71% to 24.80 billion rupees, according to a company filing. Gross collections hit around 51.0 billion rupees, while new sales bookings came in at 4.19 billion rupees.

The company reported EBITDA of roughly 8.49 billion rupees. It posted a net operating cash surplus of 38.76 billion rupees, pushing its net cash position to 116.6 billion rupees. Gross debt, defined as total borrowings before cash, stood at zero.

Revenue from operations climbed 32.2% to 20.20 billion rupees. In real estate, income usually registers as construction milestones are reached, boosting earnings even if new bookings taper off.

Sales bookings, or pre-sales, measure the value of homes sold during the period but not yet counted as revenue. They dropped sharply to 4.19 billion rupees from over 120 billion a year earlier. The decline came as DLF had no major residential launches this quarter and faced a tough comparison against the strong base set by its super-luxury Dahlias project in Gurugram.

DLF confirmed it’s holding firm to its full-year booking target of 200–220 billion rupees. Sources close to the company’s filings say it has already recorded 161.69 billion rupees in sales for the first nine months of FY26.

DLF told analysts it has “strong visibility” on upcoming launches and that bookings for Dahlias, which were on hold last quarter for a redesign, have now restarted. The company said occupancy in its rental portfolio stands above 94% by area, with Summit Plaza nearly 95% pre-leased. https://www.dlf.in/qu-result/Q3FY26-Result…

Jefferies stays bullish on DLF, forecasting roughly 63% gain from its last close, Moneycontrol reported. It’s one of eight brokerages betting the stock will top 1,000 rupees within a year. On Friday, shares kicked off at 620 rupees, climbing about 1% before slipping back.

Peers are still showing strong quarterly bookings. Godrej Properties reported sales of 84.21 billion rupees this quarter, with Lodha Developers and Prestige Estates posting 56.20 billion and 41.84 billion rupees, respectively, LiveMint noted. “Aggregate pre-sales of our universe are likely to decline, primarily driven by a sharp year-on-year fall in DLF’s pre-sales,” said Pankaj Kumar, vice president for fundamental research at Kotak Securities. https://www.livemint.com/market/stock-mark…

The coming months will be crucial, overshadowing the debt headline. Should launches delay again or premium housing demand drop harder than anticipated, bookings might remain subdued, putting the cash flow narrative under pressure.

Stock Market Today

  • Rocket Lab Stock Price Forecast: AI Analyst Cautions Despite 60% Surge
    June 9, 2026, 10:12 AM EDT. Shares of Rocket Lab USA ($RKLB) have jumped more than 60% year-to-date due to increased demand for small-satellite launches. Despite the rally, AI-driven analysis from TipRanks highlights caution, urging investors to consider potential market volatility and competitive pressures. Rocket Lab's growth taps into expanding satellite deployment, but risks remain in a crowded aerospace sector. Investors should balance optimism with these cautionary signals from advanced analytics.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
British American Tobacco share price in focus before London open after buyback disclosure
Previous Story

British American Tobacco share price in focus before London open after buyback disclosure

Experian share price rebounds after bruising slide as traders weigh Q3 update and policy risk
Next Story

Experian share price rebounds after bruising slide as traders weigh Q3 update and policy risk

Go toTop